By Sabela Ojea

Medtronic said the U.S. Food and Drug Administration has approved its PulseSelect Pulsed Field Ablation System for the treatment of two heart conditions.

The Dublin-based medical technology company on Wednesday said the company's heart technology can now treat paroxysmal and persistent atrial fibrillation following the FDA's approval.

Commercialization of the PulseSelect PFA system will start in early 2024.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

December 13, 2023 18:36 ET (23:36 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Medtronic (NYSE:MDT)
Historical Stock Chart
Von Mai 2024 bis Jun 2024 Click Here for more Medtronic Charts.
Medtronic (NYSE:MDT)
Historical Stock Chart
Von Jun 2023 bis Jun 2024 Click Here for more Medtronic Charts.